Finding how to switch the mode of action of Mkl1 between SRF transactivation versus its SAP-dependent transcriptional activity is a subject of ongoing research in our lab that in future may help with the development of new therapeutic interventions for breast cancer. This evidence concerns the gene SRF and breast carcinoma.